Metropolis Healthcare Ltd saw its non-covid revenue touch nearly 85% of last year’s level in the second quarter. While growth in revenue from coronavirus testing has been quite decent, overall revenue grew well at 29% year-on-year.
This, coupled with decent cost savings, has helped the stock rise 2% above its pre-covid highs.Metropolis has covered good ground on non-covid revenue in recent months, which could rebound to over pre-covid levels in the third quarter, say analysts.
On the other hand, the volume of covid tests has begun to reduce on a monthly basis given the moderation in covid cases.Patient visits have increased over last year’s levels, which is encouraging.